Weekly Digest - 15-21 Apr 2023
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
Weekly Digest - 15-21 Apr 2023
April 16, 2023: Pembrolizumab (IV) / Biliary Tract Cancer / Merck: Improved OS data from Phase 3 KEYNOTE-966 trial
Merck reported positive data from AACR 2023 for KEYNOTE-966 trial evaluating Pembrolizumab plus Chemo combo compared to Chemo for the 1L treatment of Biliary Tract Cancer
- This combination demonstrated statistically significant and clinically meaningful improvement in OS compared to chemo alone with median OS of 12.7 months (Pembro + Chemo) vs 10.9 months (chemo alone)
- It reduced the risk of death by 17% compared to chemo alone after a median follow-up of 25.6 months
- The safety profiles were consistent with no new safety signals
- “Based on these results, we hope to expand the use of KEYTRUDA in combination with chemo as a 1L immunotherapy option for appropriate biliary tract cancer patients. We look forward to discussing these data with regulatory authorities.” said Dr. Scot Ebbinghaus, vice president of global clinical development, Merck Research Laboratories
